An approval in China would mark a big change for Amarin...It would herald a drastic increase in the volume of sales for Vascepa and an equally drastic decease in price...After that, Vascepa might be replaced by an AG in addition to an eventual statin-MND2119 fixed dose combo for patients willing to pay extra for a once a day drug.